💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

China's illegal opioids enter U.S. through Postal Service gaps: probe

Published 01/24/2018, 06:07 PM
© Reuters. FILE PHOTO: A used needle sits on the ground in a park in Lawrence
FDX
-
UPS
-

By Richard Cowan

WASHINGTON (Reuters) - Illegal shipments of the powerful and addictive opioid fentanyl are pouring into the United States by mail from China and the U.S. Postal Service must step up the use of high-tech detection methods to fight the problem, according to a congressional report unveiled on Wednesday.

A year-long probe by a Senate Homeland Security and Government Affairs investigations subcommittee found there is easy access for buyers in the United States to purchase fentanyl, often in relatively large quantities, through the internet.

The drugs are mailed by "labs" in China to individuals who consume them or to middlemen who dilute them for resale.

Investigators refused to divulge the names of the labs.

According to the report, the U.S. Postal Service has failed to widely deploy a system to capture advanced electronic data (AED) about packages destined for American ports, which would help identify suspicious mail to be turned over to U.S. Customs and Border Protection agents.

The U.S. Postal Service said in a statement it was "working aggressively with law enforcement and key trading partners to stem the flow of illegal drugs entering the United States."

USPS is "prioritizing obtaining AED from the largest volume foreign posts, which collectively account for over 90 percent of inbound volumes," the statement added.

EXPRESS MAIL

Staff of the Permanent Investigations Subcommittee said they focused on six "very responsive" providers in China, out of hundreds of pages of websites offering fentanyl for sale.

The result was the identification of 500 online transactions involving fentanyl, mainly in powder form, with a street value of about $766 million.

U.S. fatalities linked to opioids including fentanyl have been rising dramatically and totaled more than 42,000 in 2016, according to government data.

Online sales from China tracked by the Senate investigators were linked to seven confirmed synthetic opioid-related deaths in the United States, they said.

The investigation was overseen by Republican Senator Rob Portman of Ohio, the subcommittee chairman, and Senator Tom Carper of Delaware, the panel's senior Democrat.

Investigators said the Chinese sellers were eager to ship the fentanyl using Express Mail Service, which operates worldwide through each country's postal operations, including the U.S. Postal Service.

Surcharges are applied, the investigators said, for customers demanding shipment through private delivery services, such as FedEx (NYSE:FDX), DHL and United Parcel Service (NYSE:UPS), because of the greater likelihood the goods would be seized.

The Senate investigation concluded that the U.S. Postal Service received advanced electronic data on 36 percent of all international packages, meaning about 318 million parcels last year were not monitored.

"We now know the depth to which drug traffickers exploit our mail system to ship fentanyl and other synthetic drugs into the United States," Portman said in a statement.

The Senate panel scheduled a hearing for Thursday to question postal, border protection, State Department and other officials.

© Reuters. FILE PHOTO: A used needle sits on the ground in a park in Lawrence

The report recommended tighter monitoring of international shipments, increased inspections and other steps.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.